MedTrace Logo

Independent Predictors on Clinical Outcomes in SARS-CoV2 Patients

NCT05162534 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1800

Last updated 2021-12-17

No results posted yet for this study

Summary

The clinical spectrum of COVID-19 can be very heterogeneous: from mild flu-like symptoms, to the form with severe pulmonary impairment (dyspnoea, tachypnoea, PaO2 / FiO2 ratio below 300 at arterial blood gas sampling, pulmonary infiltrates covering more than 50% of the respiratory surface); up to 5% of patients tend to rapidly develop acute respiratory distress syndrome (ARDS) with or without acute cardiac damage, underlying a phase of systemic hyperinflammation (cytokine storm) that may result in shock, multi-organ failure and death

Conditions

  • COVID-19 Patients

Interventions

OTHER

effect of COVID-19 exposure

effect of COVID-19 exposure

Sponsors & Collaborators

  • Università degli Studi di Ferrara

    collaborator OTHER

  • University Hospital of Ferrara

    lead OTHER

Principal Investigators

  • Angelina Passaro, MD · Università degli Studi di Ferrara

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-29
Primary Completion
2020-09-30
Completion
2021-07-22

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05162534 on ClinicalTrials.gov